Agios Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and delivering medicines for rare diseases, with a foundation in hematology and cellular metabolism. The company's lead product, mitapivat, is approved in the United States, European Union, Great Britain, and Saudi Arabia for the treatment of hemolytic anemias, including pyruvate kinase deficiency and alpha- or beta-thalassemia. Agios is also advancing a pipeline of investigational therapies, including tebapivat for lower-risk myelodysplastic syndromes and sickle cell disease, AG-181 for phenylketonuria, and AG-236 for polycythemia vera. The company previously sold its oncology business to Servier Pharmaceuticals in 2021, which included the clinical-stage candidate vorasidenib. Agios was founded in 2008 and maintains a partnership with Alnylam Pharmaceuticals for the development of AG-236.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage agios.com
Sector Healthcare IR page investor.agios.com
Tags
rare diseases, hematology, hemolytic anemias, pyruvate kinase deficiency, thalassemia, sickle cell disease, myelodysplastic syndromes, phenylketonuria, polycythemia vera, cellular metabolism, sirna, oncology, mitapivat, AQVESME, PYRUKYND, tebapivat, AG-181, AG-236, AG-946, vorasidenib, IDHIFA, enasidenib, TIBSOVO, ivosidenib, Alnylam Pharmaceuticals, Servier Pharmaceuticals, Royalty Pharma
Press page —

Metrics

Valuation  
Market cap $ 2.253B
Market cap (USD) $ 2.253B
P/E -5.95
PEG —
P/BV 2.30
P/S 16.00
P/OCF -6.79
P/FCF -6.71
Dividend yield —
Turnover / mcap —
Returns  
ROE -30.2%
ROI -36.7%
ROIC -31.5%
Profit margin -764.0%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 60
Quality score -43.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Revenue 54.028M 36.498M 26.823M 14.24M — 203.196M 117.912M 94.387M 43.011M — — 65.358M 25.548M 25.106M
Net profit -412.781M 673.725M -352.088M -231.801M 1.605B -327.37M -411.472M -346.028M -314.67M -198.471M -117.732M -53.504M -39.407M -20.102M
Free cash flow -377.293M -391.526M -297.061M -314.359M -413.061M -305.668M -382.793M -311.407M -289.859M 28.647M -97.113M -61.569M -57.694M -51.023M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Share price 27.22 32.86 22.27 28.08 32.87 43.33 47.75 46.11 57.17 41.73 64.92 112.04 23.95 —
Price performance 12m -0.17 0.48 -0.21 -0.15 -0.24 -0.09 0.04 -0.19 0.37 -0.36 -0.42 3.68 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — — 114M 105M 97.1M 85.7M 72M 57M 40.2M
Cash and deposits (USD) 161M 103M 70.5M 80.9M 127M 203M 139M 88.2M 76.2M 89.1M
Right-of-use assets (USD) — — — 93.6M 84.7M 75.1M 65.1M 54.4M 42.9M 30.5M
Cash flow detail
Operating cash flow (USD) 38.6M -285M -304M -371M -291M -407M -309M -296M -390M -373M
Purchases of property, plant and equipment (USD) -9.92M -4.63M -6.99M -12.2M -14.9M -5.74M -4.88M -999,000 -1.69M -4.32M
Change in receivables (cash effect) (USD) — — — — 0.00 0.00 -2.21M -604,000 -1.3M -6.47M
Change in inventories (cash effect) (USD) 0.00 0.00 -869,000 -6.46M -7.37M 0.00 -8.49M -10.6M -8.54M -5.3M
Change in payables (cash effect) (USD) 3.5M 5.33M -5.49M 3.72M 5.89M 1.86M 3.44M -8.73M 6.6M 1.75M
Income taxes paid (cash effect) (USD) — — — 0.00 0.00 -16.1M 0.00 -1.57M -43.2M -628,000
Share-based compensation (USD) 42.1M 47.8M 73.4M 72.4M 75.1M 53.5M 49.3M 44.8M 42.8M 52.6M
Operating cash flow before change in receivables (USD) — — — — -291M -407M -307M -295M -389M -367M
Free cash flow (OCF - PPE - intangibles) (USD) 28.6M -290M -311M -383M -306M -413M -314M -297M -392M -377M
Income detail
Research and development expense (USD) 220M 293M 341M 411M 367M 257M 280M 296M 301M 340M
↳ 5y CAGR +47.8% +48.1% +44.3% +32.6% +21.0% +3.1% -0.9% -2.8% -6.0% -1.6%
Total comprehensive income (USD) -198M -316M -347M -409M -327M 1.6B -243M -340M 673M -409M
Comprehensive income to owners (USD) -198M -316M -347M -409M -327M 1.6B -243M -340M 673M -409M
Reported Feb 14, 2019 Feb 14, 2019 Feb 14, 2019 Feb 24, 2022 Feb 23, 2023 Feb 23, 2023 Feb 23, 2023 Feb 15, 2024 Feb 13, 2025 Feb 12, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Nov 05, 2026

PDF Version

  • Mitapivat (PYRUKYND® and AQVESME®) delivered worldwide net revenues of $55.4 million in third quarter of 2026, more than four times the $12.9 million reported in third quarter of 2025

  • Strong U.S. demand for AQVESME in thalassemia continues, with 619 cumulative prescriptions with completed start forms from REMS-certified physicians, plus 48 additional prescriptions with start forms in process as of September 30, 2026

  • New PDUFA goal date for mitapivat sickle cell disease sNDA set for February 1, 2027; company is launch-ready and in labeling discussions with FDA

  • 14 abstracts accepted at ASH 2026, including new clinical data for mitapivat in sickle cell disease and for AG-236 in polycythemia vera, highlighting the breadth and depth of Agios’ rare hematology portfolio

  • $907.0 million in cash, cash equivalents, and marketable securities as of September 30, 2026, fully funding commercial launches and pipeline programs; company is targeting non-GAAP profitability in 2028

CAMBRIDGE, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and updates for the third quarter ended September 30, 2026.

“The third quarter was a record for our product revenue, outperforming our entire 2025 total in just three months. This growth was driven by the U.S. commercial launch of AQVESME in thalassemia, where broadening demand is translating into a durable base of patients on therapy,” said Brian Goff, Chief Executive Officer, Agios. “This launch has built the commercial foundation for our largest indication opportunity with mitapivat – sickle cell disease. Our conviction in mitapivat for patients with sickle cell disease is grounded in the robust efficacy and safety data generated to date and we are launch-ready ahead of our PDUFA goal date of February 1, 2027. With this commercial infrastructure, alongside a strong balance sheet and a disciplined operating model, Agios is well positioned for sustained growth as a focused, rare hematology company.”

Third Quarter 2026 and Recent Corporate Highlights

  • Mitapivat (PYRUKYND® and AQVESME®) Commercial Performance and Update –

  • $48.7 million in U.S. net revenue and $6.6 million in ex-U.S. net revenue in the third quarter of 2026

  • U.S. net revenue increased 20% sequentially, driven by the U.S. commercial launch of AQVESME (mitapivat) in thalassemia in late January 2026.

  • Ex-U.S. net revenue increased 74% sequentially, driven primarily by early access programs in Europe following the late May 2026 approval of PYRUKYND (mitapivat) in thalassemia in the European Union. This robust, early momentum underscores the strong global opportunity for mitapivat, which the company is advancing through capital-efficient partnerships with Avanzanite Bioscience B.V. in Europe and NewBridge Pharmaceuticals in the Gulf Cooperation Council (GCC) region.

  • AQVESME demand continues to expand following the January 2026 U.S. commercial launch in thalassemia

  • In the third quarter, 177 AQVESME prescriptions with completed Agios start forms (ASFs) were written by Risk Evaluation and Mitigation Strategy (REMS)-certified U.S. physicians, bringing cumulative prescriptions to 619 as of September 30, 2026.

  • An additional 48 cumulative prescriptions had ASFs in process as of September 30, 2026, which are not included in the reported metric above.

  • Demand continues to broaden, with deeper penetration in transfusion-dependent patients and expansion into the larger non-transfusion dependent population. Approximately 75% of patients remain on AQVESME after six months of treatment.

  • Operating Model Update –

  • Over the course of 2026, Agios reviewed its operating model, and will have reduced its R&D headcount by over 100 roles by year-end, representing a more than 35% decrease compared with 2025. The company expects the associated cost savings of these reductions to be realized in 2027.

Research and Development (R&D) Highlights

  • Mitapivat (pyruvate kinase [PK] activator) –

  • Sickle Cell Disease –

  • Agios announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its mitapivat sickle cell disease supplemental New Drug Application (sNDA) by three months, from November 1, 2026, to February 1, 2027.

  • The FDA recently requested additional information to evaluate whether a REMS is necessary for mitapivat in sickle cell disease. The FDA classified Agios’ response to this information request as a major amendment to the sNDA, resulting in the three-month review extension.

  • Agios will continue its labeling discussions with the FDA as part of the ongoing sNDA review, including elements of a potential REMS.

  • American Society of Hematology (ASH) Annual Meeting and Exposition (ASH 2026) –

  • Agios announced that 14 abstracts led by Agios and external collaborators have been accepted for presentation and publication at ASH 2026, taking place December 12-15, 2026, in New Orleans, Louisiana. These include three oral presentations featuring new data across mitapivat clinical programs.

  • New clinical data from the RISE UP Phase 3 trial of mitapivat in sickle cell disease shows durable hemoglobin improvements for up to 115 weeks (over two years) with continued treatment. Additional post-hoc RISE UP analyses show the potential for mitapivat to improve measures of kidney function and cardiac remodeling in this population, which may reflect its unique dual activation of two pyruvate kinase isoforms: PKR, expressed in red blood cells, and PKM2, expressed in organ tissues.

  • The first clinical data for AG-236 from a Phase 1 trial in healthy volunteers support every-six-month dosing in polycythemia vera, supporting a potential best-in-class profile.

Third Quarter 2026 Financial Results For the quarter ended September 30, 2026, net loss was $65.0 million, compared to net loss of $103.4 million for the quarter ended September 30, 2025.

  • Net product revenue from U.S. salesof mitapivat (PYRUKYND and AQVESME) for the third quarter of 2026 was $48.7 million, compared to $12.3 million for the third quarter of 2025.

  • Net product revenue from ex-U.S. salesof mitapivat (PYRUKYND) for the third quarter of 2026 was $6.6 million, compared to $0.6 million for the third quarter of 2025.

  • Cost of salesfor the third quarter of 2026 was $2.5 million.

  • Research and Development (R&D) expenseswere $73.5 million for the third quarter of 2026, compared to $86.8 million for the third quarter of 2025, driven primarily by reductions in spend associated with mitapivat and tebapivat process development and certain clinical trials.

  • Selling, General and Administrative (SG&A) expenses were $56.5 million for the third quarter of 2026, compared to $41.3 million for the third quarter of 2025, due to an increase in activities supporting the U.S. commercial launch of AQVESME in thalassemia and preparation for the potential U.S. commercial launch of mitapivat in sickle cell disease.

  • Cash, cash equivalents and marketable securities were $907.0 million as of September 30, 2026, compared to $1.2 billion as of December 31, 2025. Agios expects that its cash, cash equivalents and marketable securities, together with anticipated product revenue and interest income, will provide the financial independence to execute the U.S. commercial launch of AQVESME in thalassemia, prepare for the potential U.S. commercial launch of mitapivat in sickle cell disease, and progress the company’s pipeline. Agios’ goal is to achieve non-Generally Accepted Accounting Principles (GAAP) profitability in 2028.

Third Quarter 2026 Conference Call Information Agios will host a conference call and live webcast today, November 5, 2026, at 8:00 a.m. ET to discuss the company’s third quarter 2026 financial results and recent business highlights. The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the “Events & Presentations” tab. A replay of the webcast will be available on the company’s website approximately two hours after the event.

About Agios: Fueled by Connections to Transform Rare Diseases™ At Agios, our vision is to redefine the future of rare disease treatment. Fueled by connections, we build trusted partnerships with communities – collaborating to develop and deliver innovative medicines that have the potential to transform lives. With a foundation in hematology, we combine biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve. Agios is a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. To learn more, visit www.agios.com and follow us on LinkedIn and X.

Available Information about Agios To achieve broad dissemination, Agios may disclose information to the public through a variety of disclosure channels including press releases, SEC filings, and public conference calls and webcasts. Some of the information distributed through these disclosure channels may be considered material information. Investors and others should note that Agios plans to use its website (www.agios.com) as a distribution channel to announce and give notice of Agios’ upcoming events and presentations (including, but not limited to, presentations at medical or healthcare conferences). Such information, which may be deemed material, will be available on the Investors section of the company’s website under the “Events & Presentations” tab. In addition, you may sign up to automatically receive email alerts about Agios’ upcoming events and presentations (“Calendar Alerts”) by visiting the “Email Alerts” option under the “IR Resources” tab of the Investors section of the company’s website and submitting your email address.

Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the potential benefits of PYRUKYND® (mitapivat), AQVESME® (mitapivat), and AG-236; Agios’ plans, strategies and expectations for its preclinical, clinical and commercial advancement of its drug development, including mitapivat and AG-236; Agios’ expectations for the review of marketing applications for mitapivat by regulatory agencies, including the FDA; Agios’ strategic vision and goals; and the potential benefits of Agios’ strategic plans and focus. The words “anticipate,” “expect,” “goal,” “hope,” “milestone,” “plan,” “potential,” “possible,” “strategy,” “will,” “vision,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios’ current expectations and beliefs. For example, there can be no guarantee that any product candidate Agios is developing will successfully commence or complete necessary preclinical and clinical development phases, or that development of any of Agios’ product candidates will successfully continue. There can be no guarantee that any positive developments in Agios’ business will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other important factors, including, without limitation: risks and uncertainties related to the impact of pandemics or other public health emergencies to Agios’ business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products; Agios’ results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. FDA, the EMA or other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Agios’ ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; competitive factors; Agios' ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; Agios’ ability to establish and maintain key collaborations; uncertainty regarding any royalty payments related to the sale of its oncology business or any milestone or royalty payments related to its in-licensing of AG-236 and cevidoplenib, and the uncertainty of the timing of any such payments; uncertainty of the results and effectiveness of the use of Agios’ cash and cash equivalents; and general economic and market conditions. These and other risks are described in greater detail under the caption "Risk Factors" included in Agios’ public filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

| Consolidated Balance Sheet Data |

| (in thousands) |

| (Unaudited) |

| | | | | | |

| | September 30, 2026 | | December 31, 2025 |

| Cash, cash equivalents, and marketable securities | $ | 907,018 | | | $ | 1,164,438 | |

| Accounts receivable, net | | 25,254 | | | | 10,577 | |

| Inventory | | 37,841 | | | | 32,920 | |

| Total assets | | 1,064,040 | | | | 1,297,225 | |

| Stockholders' equity | | 979,336 | | | | 1,193,114 | |

| Consolidated Statements of Operations Data (in thousands, except share and per share data) (Unaudited) |

| | | | | | | | | | | | |

| | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | 2026 | | 2025 | | 2026 | | 2025 |

| Revenues: | | | | | | | | | | | |

| Product revenue, net | $ | 55,385 | | | $ | 12,880 | | | $ | 120,876 | | | $ | 34,061 | |

| Total revenue | | 55,385 | | | | 12,880 | | | | 120,876 | | | | 34,061 | |

| Operating expenses: | | | | | | | | | | | |

| Cost of sales | $ | 2,525 | | | $ | 1,679 | | | $ | 6,840 | | | $ | 4,466 | |

| Research and development | | 73,487 | | | | 86,796 | | | | 255,389 | | | | 251,479 | |

| Selling, general and administrative | | 56,533 | | | | 41,274 | | | | 156,384 | | | | 128,670 | |

| Total operating expenses | | 132,545 | | | | 129,749 | | | | 418,613 | | | | 384,615 | |

| Loss from operations | | (77,160 | ) | | | (116,869 | ) | | | (297,737 | ) | | | (350,554 | ) |

| Royalty income from gain on sale of oncology business | | 2,969 | | | | — | | | | 2,969 | | | | — | |

| Interest income, net | | 8,880 | | | | 13,369 | | | | 29,405 | | | | 43,969 | |

| Other income, net | | 266 | | | | 67 | | | | 504 | | | | 1,843 | |

| Net loss | $ | (65,045 | ) | | $ | (103,433 | ) | | $ | (264,859 | ) | | $ | (304,742 | ) |

| Net loss per share - basic and diluted | $ | (1.09 | ) | | $ | (1.78 | ) | | $ | (4.46 | ) | | $ | (5.27 | ) |

| Weighted-average number of common shares used in computing net loss per share – basic and diluted | | 59,707,904 | | | | 58,139,277 | | | | 59,329,729 | | | | 57,846,173 | |

| | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | |

Nov 04, 2026

PDF Version

  • 14 abstracts accepted at ASH 2026, including three oral presentations featuring new data across mitapivat clinical programs

  • New analyses from RISE UP Phase 3 trial of mitapivat in sickle cell disease show durable hemoglobin improvements for up to two years, as well as potential kidney and cardiac health benefits

  • First AG-236 clinical data from Phase 1 trial in healthy volunteers support every-six-month dosing in polycythemia vera, supporting a potential best-in-class profile

  • Agios will host ASH 2026 virtual investor event on Monday, December 14, at 1:00 p.m. EST (12:00 p.m. CST)

CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that new clinical data across the company’s rare hematology portfolio will be featured in oral and poster presentations during the 68th American Society of Hematology (ASH) Annual Meeting and Exposition (ASH 2026) in New Orleans, Louisiana, December 12-15, 2026.

“As Agios continues to expand its impact across rare hematologic diseases, ASH 2026 represents a key opportunity to highlight the strength and differentiation of our portfolio,” said Sarah Gheuens, M.D., Ph.D., Chief Medical Officer and Head of R&D, Agios. “In sickle cell disease, new clinical data from the RISE UP Phase 3 trial show that mitapivat can deliver durable hemoglobin improvements for up to two years. RISE UP analyses also show the potential for mitapivat to improve measures of kidney function and cardiac remodeling in this population, which may reflect its unique dual activation of two pyruvate kinase isoforms – PKR expressed in red blood cells and PKM2 expressed in organ tissues. We will also present the first data from our AG-236 clinical program showing sustained, on-target activity that supports an every-six-month dosing schedule in polycythemia vera, potentially offering patients a best-in-class profile. Together, our ASH 2026 data reinforce the potential for these medicines to transform the treatment of rare hematologic diseases with significant patient needs, and we look forward to sharing them with the hematology community at the congress next month.”

Select Presentations at ASH 2026 Mitapivat, oral pyruvate kinase (PK) activator

  • An oral presentation describing hemoglobin improvements with long-term mitapivat treatment (up to 115 weeks) among patients with sickle cell disease in the open-label extension (OLE) period of the RISE UP Phase 3 trial, during which all patients receive mitapivat. Of the 176 patients who completed the double-blind period of RISE UP, a total of 174 (118 from the mitapivat arm and 56 from the placebo arm) enrolled in the OLE period. Among all 118 patients continuing on mitapivat, 62.7% (n=74) achieved a hemoglobin improvement (defined as ≥1.0 g/dL increase from baseline in average hemoglobin during any two consecutive study visits) during the OLE period. Notably, of the 63 non-responders during the double-blind period, 39.7% (n=25) achieved a hemoglobin improvement with continued mitapivat treatment during the OLE period. Additionally, of the 56 patients who crossed over from placebo to mitapivat, 51.8% (n=29) achieved a hemoglobin improvement during the OLE period. The safety profile in the OLE period was consistent with that observed during the double-blind period. These results continue to support the potential of mitapivat as a durable, disease-modifying treatment for patients with sickle cell disease.

  • An oral presentation evaluating changes in kidney filtration rate, as measured by estimated glomerular filtration rate (eGFR), during the double-blind period of the RISE UP Phase 3 trial of mitapivat in sickle cell disease. In this condition, chronic hemolysis and anemia can cause the kidney to filter blood at an abnormally high rate (indicated by elevated eGFR), and this hyperfiltration is associated with long-term kidney damage. In a post hoc analysis, patients who received mitapivat had an early and sustained reduction in eGFR: among 132 patients with hyperfiltration (eGFR >135 mL/min/1.73 m²) at baseline, mitapivat-treated patients (n=92) showed a 14.7 mL/min/1.73 m² decrease in eGFR at Week 52, compared with a 4.9 mL/min/1.73 m² decrease with placebo (n=40). This reduction was observed regardless of whether patients achieved a hemoglobin response; taken together, these data suggest that the renal effects of mitapivat may be driven by both PKR- and PKM2-mediated mechanisms.

  • A poster presentation showing favorable cardiac remodeling among patients with sickle cell disease who achieved a hemoglobin response with mitapivat during the double-blind period of the RISE UP Phase 3 trial. This effect was evaluated by left ventricular mass index (LVMI) and left atrial volume index (LAVI), two measures of cardiac size and structure that can be abnormally elevated in sickle cell disease due to chronic hemolysis and anemia. This post hoc analysis found that, at Week 52, LVMI decreased from baseline by 5.9 g/m² among hemoglobin responders in the mitapivat arm (n=40), whereas it increased by 5.8 g/m² among non-responders (n=45) and by 4.6 g/m² in the placebo group (n=27). Hemoglobin responders also achieved a greater decrease from baseline in LAVI at Week 52 (4.7 mL/m²; n=35) compared with non-responders (1.7 mL/m²; n=41) and the placebo group (0.2 mL/m²; n=27). These data indicate that the anti-hemolytic effect of mitapivat may be a key driver of these improvements in cardiac remodeling, which, alongside preclinical evidence showing that PKM2 activation can attenuate cardiac fibrosis, suggests a potential dual cardiac benefit of mitapivat.

AG-236, small interfering RNA (siRNA) targeting TMPRSS6

  • A poster presentation highlighting first-in-human data from a Phase 1 single ascending dose study of AG-236 in 24 healthy volunteers. The study showed that AG-236 produced sustained increases in hepcidin – a key regulator of iron homeostasis – and decreases in circulating iron availability, including reductions in serum iron and transferrin saturation through Month 6 post-dose. Biomarkers of erythropoiesis (red cell production), hemoglobin and hematocrit, were also reduced through Month 6. AG-236 was well tolerated across all dose levels (1.0, 3.0, and 9.0 mg/kg), with no serious adverse events and no dose-limiting toxicities. In July 2026, Agios announced plans to advance AG-236 into a Phase 2/3 development program in polycythemia vera, with initiation of the Phase 2 portion expected in the second half of 2026.

In total, 14 abstracts led by Agios and external collaborators have been accepted for presentation and publication at ASH 2026.

ASH 2026 Accepted Abstracts

| Title | Number | Date/Time | Presenter | Acceptance |

| Sickle Cell Disease |

| Long-term hemoglobin response from the Phase 3 RISE UP trial of mitapivat in patients with sickle cell disease | 336 | Saturday, December 12, 2026, 5:15 – 5:30 p.m. CST | Kevin Kuo, M.D., University of Toronto | Oral |

| Mitapivat is associated with early and sustained improvements in eGFR among patients with sickle cell disease: A post hoc analysis of the Phase 3 RISE UP trial | 741 | Monday, December 14, 2026, 11:00 – 11:15 a.m. CST | Kenneth Ataga, M.D., Center for Sickle Cell Disease at University of Tennessee Health Science Center | Oral |

| Mitapivat is associated with favorable cardiac remodeling in hemoglobin responders with sickle cell disease: A post hoc analysis of the Phase 3 RISE UP trial | 1158 | Saturday, December 12, 2026, 5:30 – 7:30 p.m. CST | David Tofovic, M.D., University of Illinois Hospital | Poster |

| Mitapivat rapidly restores red blood cell membrane integrity: A window for pre-emptive intervention in sickle cell vaso- occlusive crisis | 1149 | Saturday, December 12, 2026, 5:30 – 7:30 p.m. CST | Swee Lay Thein, MBBS, DSc, FRCP, FRCPath, MRCP, MRCPath, National Heart, Lung & Blood Institute | Poster |

| Ongoing burden of sickle cell disease among individuals treated with newly approved disease-modifying therapies: A real-world claims analysis using United States Medicaid data | 4434 | Sunday, December 13, 2026, 6:00 – 8:00 p.m. CST | Nirmish Shah, M.D., Duke University Adult Comprehensive Sickle Cell Center | Poster |

| Longitudinal trends in renal biomarkers of US patients with sickle cell nephropathy | 4712 | Monday, December 14, 2026, 6:00 – 8:00 p.m. CST | Santosh Saraf, M.D., University of Illinois Hospital | Poster |

| Impact of patient- reported pain crises on the lives of adults with sickle cell disease in the United States: Results from the real-world RAISE study | 6194 | Monday, December 14, 2026, 6:00 – 8:00 p.m. CST | Sherif Badawy, M.D., Northwestern University Feinberg School of Medicine | Poster |

| Trial in progress: Study design of the randomized, double- blind, Phase 3 REIGNITE trial to evaluate the effect of mitapivat versus placebo on transfusion burden in patients with sickle cell disease | 4686 | Monday, December 14, 2026, 6:00 – 8:00 p.m. CST | Julia Xu, M.D., MScGH, University of Pittsburgh Medical Center | Poster |

| Mitapivat promotes terminal erythroid maturation in patient- derived sickle cell disease erythroid cultures | 4668 | Monday, December 14, 2026, 6:00 – 8:00 p.m. CST | Dr. Wassim El Nemer, Ph.D., French National Blood Service (EFS) | Poster |

| Relationship between markers of hemolysis and clinical outcomes in sickle cell disease: A systematic literature review and meta-analysis | N/A | N/A | Kenneth Ataga, M.D., Center for Sickle Cell Disease at University of Tennessee Health Science Center | Publication |

| Thalassemia |

| Long-term changes in iron overload and markers of iron regulation and erythropoiesis with mitapivat in patients with α– or β–non–transfusion- dependent thalassemia: Results from the Phase 3 ENERGIZE open-label extension | 9 | Saturday, December 12, 2026, 10:00 – 10:15 a.m. CST | Hanny Al-Samkari, M.D., Mass General Brigham Cancer Institute | Oral |

| Clinical and patient- centered implications of reduced transfusion burden with mitapivat in transfusion-dependent thalassemia: A post hoc analysis of ENERGIZE-T | 4655 | Monday, December 14, 2026, 6:00 – 8:00 p.m. CST | Sujit Sheth, Weill Cornell Medicine | Poster |

| Polycythemia Vera |

| Safety and tolerability of AG-236, an investigational TMPRSS6- targeting small interfering RNA for polycythemia vera, in healthy participants | 3772 | Sunday, December 13, 2026, 6:00 – 8:00 p.m. CST | Jonathan Meiman, M.D., University of Wisconsin- Madison | Poster |

| Other Conditions |

| Distinct metabolic signatures differentiate Rps19 and Rpl5 haploinsufficiency in Diamond-Blackfan Anemia syndromes | 3183 | Sunday, December 13, 2026, 6:00 – 8:00 p.m. CST | Jonathan de Wilde, M.D., University Medical Center Utrecht, Netherlands | Poster |

| | | | | |

Please refer to the ASH 2026 website for full session details and data presentation listings and visit the Agios booth (#929) onsite.

ASH 2026 Investor EventAgios will host an ASH 2026 virtual investor event on Monday, December 14, at 1:00 p.m. EST (12:00 p.m. CST). The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the “Events & Presentations” tab. A replay of the webcast will be available on the company’s website approximately two hours after the event.

About Mitapivat in Sickle Cell Disease Sickle cell disease is a rare, inherited blood disorder in which abnormal hemoglobin causes red blood cells to become rigid and sickle-shaped, leading to chronic hemolysis (red blood cell destruction) that contributes to severe anemia and progressive, life-threatening complications, including damage to the lungs, kidneys, and heart. Mitapivat is an oral medicine designed to enhance red blood cell energy by activating the pyruvate kinase (PK) enzyme, which can increase levels of adenosine triphosphate (ATP) and lower levels of 2,3-diphosphoglycerate (2,3-DPG). Mitapivat has a unique dual mechanism of action that activates two isoforms of the PK enzyme – PKR expressed in red blood cells and PKM2 expressed in organ tissues – and has shown the potential to address both chronic hemolysis and pathways involved with long-term organ damage.

In July 2026, Agios announced that the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) for mitapivat in sickle cell disease with a Priority Review. In October 2026, Agios announced the FDA extended the Prescription Drug User Fee Act (PDUFA) goal date for this sNDA by three months, from November 1, 2026, to February 1, 2027. The mitapivat sNDA is based on data from the global, randomized, double-blind, placebo-controlled RISE UP Phase 2 and Phase 3 trials (NCT05031780) in patients aged 16 years or older with sickle cell disease.

About AG-236 in Polycythemia Vera Polycythemia vera (PV) is a rare blood cancer characterized by the overproduction of blood cells driven by an underlying genetic mutation in Janus kinase 2 (JAK2). Patients with PV typically have reduced levels of hepcidin, a critical hormone that regulates iron in the body. AG-236 is an investigational, small interfering RNA (siRNA) designed to silence the expression of the transmembrane serine protease 6 (TMPRSS6) gene, which normally downregulates hepcidin. By silencing TMPRSS6, AG-236 is designed to upregulate hepcidin, thereby restricting iron availability and controlling the overproduction of red blood cells associated with PV.

Based on promising results in a Phase 1 trial in healthy volunteers, Agios is advancing AG-236 into a Phase 2/3 development program (NCT07859423) in polycythemia vera, with initiation of the Phase 2 portion expected in the second half of 2026.

AG-236 is licensed from Alnylam Pharmaceuticals, Inc.

About Agios: Fueled by Connections to Transform Rare Diseases™ At Agios, our vision is to redefine the future of rare disease treatment. Fueled by connections, we build trusted partnerships with communities – collaborating to develop and deliver innovative medicines that have the potential to transform lives. With a foundation in hematology, we combine biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve. Agios is a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. To learn more, visit www.agios.com and follow us on LinkedIn and X.

Available Information about Agios To achieve broad dissemination, Agios may disclose information to the public through a variety of disclosure channels including press releases, SEC filings, and public conference calls and webcasts. Some of the information distributed through these disclosure channels may be considered material information. Investors and others should note that Agios plans to use its website (www.agios.com) as a distribution channel to announce and give notice of Agios’ upcoming events and presentations (including, but not limited to, presentations at medical or healthcare conferences). Such information, which may be deemed material, will be available on the Investors section of the company’s website under the “Events & Presentations” tab. In addition, you may sign up to automatically receive email alerts about Agios’ upcoming events and presentations (“Calendar Alerts”) by visiting the “Email Alerts” option under the “IR Resources” tab of the Investors section of the company’s website and submitting your email address.

Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the potential benefits of mitapivat and AG-236; Agios’ plans regarding future data presentations; and the potential benefits of Agios’ strategic plans and focus. The words “anticipate,” “expect,” “goal,” “hope,” “milestone,” “plan,” “potential,” “possible,” “strategy,” “will,” “vision,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios’ current expectations and beliefs. For example, there can be no guarantee that any product candidate Agios is developing will successfully commence or complete necessary preclinical and clinical development phases, or that development of any of Agios’ product candidates will successfully continue. There can be no guarantee that any positive developments in Agios’ business will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other important factors, including, without limitation: risks and uncertainties related to the impact of pandemics or other public health emergencies to Agios’ business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products; Agios’ results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. FDA, the EMA or other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Agios’ ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; competitive factors; Agios’ ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; Agios’ ability to establish and maintain key collaborations; uncertainty regarding any royalty payments related to the sale of its oncology business or any milestone or royalty payments related to its in-licensing of AG-236 and cevidoplenib, and the uncertainty of the timing of any such payments; uncertainty of the results and effectiveness of the use of Agios’ cash and cash equivalents; and general economic and market conditions. These and other risks are described in greater detail under the caption “Risk Factors” included in Agios’ public filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Oct 30, 2026

PDF Version

  • FDA recently requested additional information to evaluate whether a REMS is necessary for mitapivat in sickle cell disease

  • FDA classified Agios’ response to the information request as a major amendment to the mitapivat sNDA, resulting in a three-month review extension

  • Mitapivat sNDA was submitted under the FDA’s accelerated approval pathway and granted Priority Review, with an original PDUFA goal date of November 1, 2026

  • Agios will continue its labeling discussions with the FDA as part of the ongoing sNDA review, including elements of a potential REMS

CAMBRIDGE, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for the supplemental New Drug Application (sNDA) for mitapivat, an oral pyruvate kinase (PK) activator, in sickle cell disease. The PDUFA goal date for this sNDA, which was submitted under the FDA’s accelerated approval pathway and granted Priority Review, is now February 1, 2027.

On October 9, 2026 – three weeks before the original PDUFA goal date for the sNDA – the FDA requested additional information to evaluate whether a Risk Evaluation and Mitigation Strategy (REMS) is necessary for mitapivat in sickle cell disease. On October 19, 2026, Agios submitted its response, which included approximately nine months of updated safety data through October 9, 2026, from the ongoing open-label extension periods of the RISE UP Phase 2 and Phase 3 trials. With this additional follow-up, there continue to be no cases of hepatocellular injury (HCI) among patients with sickle cell disease treated with mitapivat that show a pattern and severity similar to those observed in the clinical trials for mitapivat in adults with thalassemia. The benefit-risk profile of mitapivat in sickle cell disease remains unchanged. On October 28, 2026, the FDA informed Agios that the company’s response had been classified as a major amendment to the sNDA, resulting in a three-month review extension.

Agios will continue its labeling discussions with the FDA, including elements of a potential REMS, and will keep working closely with the agency to bring mitapivat to patients with sickle cell disease, a community with significant unmet need, as soon as possible.

“We have strong conviction in mitapivat’s potential to transform care for people living with sickle cell disease, grounded in the comprehensive data from the RISE UP clinical program and further supported by the additional data we submitted in response to the FDA’s recent request. The FDA granted this application Priority Review, underscoring the serious need in this disease, and that urgency has not changed,” said Brian Goff, Chief Executive Officer, Agios. “Sickle cell disease affects approximately 100,000 people in the U.S. and is the largest indication we have pursued for mitapivat, and we expect it to be a significant growth driver for Agios. We are launch-ready, building on our commercial infrastructure and the strong relationships we have established over several years with hematologists, sickle cell centers, and patients. We will continue to work expeditiously with the goal of bringing mitapivat to patients with sickle cell disease as soon as possible.”

The mitapivat sNDA is based on data from the global, randomized, double-blind, placebo-controlled RISE UP Phase 2 and Phase 3 trials in patients aged 16 years or older with sickle cell disease. Mitapivat is currently approved in the U.S. for adult patients in two hemolytic anemias: pyruvate kinase (PK) deficiency (2022) and thalassemia (2025).

Prompts

Agios Pharmaceuticals, Inc. (ticker AGIO), listed in United States.

ETFs Holding Agios Pharmaceuticals, Inc.

ETF Weight in ETF Shares Market value As of
FSEV 0.19% 350 $ 12.989K Jun 30, 2026
AVSC 0.12% 123,808 $ 3.733M Nov 16, 2026
RESM 0.07% 65 $ 2,412.15 Jun 30, 2026
DFAS 0.04% 435,455 $ 13.83M Nov 12, 2026
FESM 0.02% 31,448 $ 1.167M Jun 30, 2026
DXUV 0.01% 27,243 $ 865.238K Nov 12, 2026
AVSU 0.01% 1,068 $ 32.2K Nov 16, 2026
DFAC 0.01% 259,958 $ 8.256M Nov 12, 2026
MSSM 0.01% 1,336 $ 44.996K Aug 31, 2026
DCOR 0.01% 72,940 $ 2.317M Nov 12, 2026
DFAU 0.00% 17,627 $ 559.834K Nov 12, 2026
DFUS 0.00% 20,228 $ 642.441K Nov 12, 2026
AVUS 0.00% 15,581 $ 469.767K Nov 16, 2026
NTRL short 0.00% -5,622 $ 0.00 Nov 16, 2026